Long-term natural history study elucidates the genetic mechanisms of autoinflammatory diseases

This long-term natural history study, led by NHGRI (National Human Genome Research Institute), began on March 10, 1994, and continues to this day. Beyond testing drug efficacy, its purpose is to elucidate the genetic causes of autoinflammatory diseases (Autoinflammatory Disease) such as Familial Mediterranean Fever (FMF). Researchers analyze leukapheresis data to observe abnormal mechanisms of immune cells at the molecular level. The genomic map obtained in this process provides crucial clues for increasing the diagnostic rate of rare diseases and developing targeted therapies.

Paradigm shift in immunology brought about by the identification of the MEFV gene and the Pyrin protein

This observational study played a key role in the 1997 identification by an international consortium of the MEFV (Mediterranean Fever) gene, the primary cause of FMF. The Pyrin protein, encoded by the MEFV gene, regulates the activity of the inflammasome, an intracellular complex that controls innate immunity (Innate Immunity). Mutations in this gene lead to the development of autoinflammatory diseases, as the Pyrin protein fails to function properly, resulting in uncontrolled inflammation. This marked a historical turning point in the establishment of autoinflammatory diseases as a distinct medical concept from autoimmune diseases.

Simultaneous growth of the biologics market to overcome colchicine resistance

Colchicine is the primary standard treatment for FMF, but 10-15% of patients are resistant to the drug or experience adverse effects. Ilaris (active ingredient: Canakinumab), a monoclonal antibody targeting interleukin-1 beta (IL-1β) from Novartis (NVS), is a representative second-line drug developed to treat these patients. Ilaris was approved by the FDA in September 2016 as the first biologic for FMF, TRAPS, and HIDS/MKD. This study served as a foundation for precisely validating clinical targets, enabling the market entry of subsequent targeted therapies such as Ilaris.

High growth potential and commercial value of the rare disease drug market

The market for periodic fever syndrome treatments, including FMF, continues to grow rapidly and is considered a highly attractive area. The global FMF treatment market is projected to grow at an annual rate of approximately 4-5%, reaching USD 2.21 billion in 2030 and USD 2.52 billion in 2032. In fact, Novartis' Ilaris achieved annual sales of USD 1.883 billion in 2025, maintaining a strong growth trend compared to the previous year. Rare disease drugs with genetically targeted therapies are highly attractive for investment due to their high prices and exclusivity.

Increasing the success rate of new drug development by securing genetic biomarkers

Rare autoinflammatory diseases have a small patient population and complex pathophysiology, making clinical design and endpoint setting challenging. NHGRI's study builds a biomarker library by analyzing patients' phenotypes and genetic variations, reducing the uncertainty of new drug development. Developers can use this data to pre-screen potential adverse effects of clinical candidates and narrow the target patient population, significantly increasing the success rate. Companies developing competing pipelines, such as Sobi's Kineret (active ingredient: Anakinra), are also actively referencing this natural history data for clinical optimization.